MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 134, Issue 10, Pages 2424-2436
Publisher
Wiley
Online
2013-10-29
DOI
10.1002/ijc.28566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
- (2013) F Zagouri et al. BRITISH JOURNAL OF CANCER
- cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
- (2012) K. P. Raghav et al. CLINICAL CANCER RESEARCH
- Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer
- (2012) S Gastaldi et al. ONCOGENE
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
- (2011) Xuefeng Liu et al. AMERICAN JOURNAL OF PATHOLOGY
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
- (2010) Yoon-La Choi et al. BMC CANCER
- Use of standard markers and incorporation of molecular markers into breast cancer therapy
- (2010) Manfred Kaufmann et al. CANCER
- MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth
- (2010) Y.-W. Zhang et al. CANCER RESEARCH
- Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells
- (2010) F. Hochgrafe et al. CANCER RESEARCH
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
- (2009) S Agarwal et al. BRITISH JOURNAL OF CANCER
- Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
- (2009) C. R. Graveel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
- (2009) M. G. Ponzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Met and c-Src Cooperate to Compensate for Loss of Epidermal Growth Factor Receptor Kinase Activity in Breast Cancer Cells
- (2008) K. L. Mueller et al. CANCER RESEARCH
- Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
- (2008) D. L. Shattuck et al. CANCER RESEARCH
- Drug development of MET inhibitors: targeting oncogene addiction and expedience
- (2008) Paolo M. Comoglio et al. NATURE REVIEWS DRUG DISCOVERY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More